Stock Investment Opportunities: Moderna and DexCom with High Growth Potential

Stock Investment Opportunities: Moderna and DexCom with High Growth Potential

Patience often pays off in the equity markets. Equities have been on a bull run for well over a year. Though it might be tempting to invest in stocks that have largely been in tandem with the broader market, it's even better to consider those companies that have failed to keep pace, provided they display solid upside potential.

1. Moderna

Moderna is one of the captains of a sinking ship. As a leader in the COVID-19 vaccine market, the biotech is seeing its sales decline rapidly as the need for vaccines subsides. In the first quarter, the company's sales came in at $167 million -- much lower than the $1.9 billion reported during the year-ago period. On the bottom line, Moderna went from net earnings of $0.19 per share in the year-ago quarter to a net loss of $3.07 in the latest quarter.

• Moderna is inching closer to launching a new product: a vaccine for the respiratory syncytial virus (RSV).
• The company's late-stage pipeline looks promising with candidates like a vaccine for cytomegalovirus (CMV) and a combined COVID-19/flu vaccine.
• Despite recent underperformance, Moderna's innovative potential indicates future market-beating returns.

2. DexCom

DexCom specializes in diabetes care, focusing on CGM systems that help patients monitor blood sugar levels. The company's revenue has continued to grow, driven by increased adoption of CGM technology.

1. Third-party payer coverage expansion and physician prescriptions are boosting CGM adoption rates.
2. Untapped market opportunities and strong financial results indicate a bright future for DexCom.

Investors with a long-term focus can confidently consider investing in both Moderna and DexCom for potential high returns.